On February 25th, 2026, Men’s Health featured insights from AFAR Board Members and grantees Nir Barzilai, MD, andMark Lachs, MD, on technological innovations and medical advancements that could extend healthspan.
Dr. Barzilai and Dr. Lachs discussed the future of therapeutics to treat or delay age-related diseases and extend healthspan, emphasizing the importance of validating drug effectiveness for targeting aging through clinical trials.
In addition to serving on AFAR’s Board of Directors, Dr. Barzilai is the 2010 recipient of the Irving S. Wright Award of Distinction, a 1997 Paul B. Beeson Emerging Leaders Career Development Award in Aging Scholar, and a 1994 AFAR Research Grant recipient, as well as Co-Investigator of the AFAR SuperAgers Family Study. He also directs the Institute for Aging Research at the Paul F. Glenn Center for the Biology of Human Aging Research at Albert Einstein College of Medicine and is the President of the Academy of Health and Lifespan Research.
In addition to being an AFAR Board member, Dr. Lachs is a 1995 Beeson Scholar.Dr. Lachs is the Irene & I. Roy Psaty Distinguished Professor of Medicine and Co-Chief of Geriatrics & Palliative Medicine at Weill Cornell Medical College, as well as the Director of Geriatrics at New York-Presbyterian Health Care System, and the Founder of the NYC Elder Abuse Center.
Also picked up by AOL, read “How New Longevity Tech Could Help You Reach 100” in Men’s Health here.
For more insights from Dr. Barzilai into the current state of existing and emerging drug interventions to extend healthspan, watch our recent webinar “The State of Gerotherapeutics: Next-Gen Interventions to Extend Healthy Living” here.
